The AGOG (Australian Genomics and Clinical Outcomes of Glioma) Epidemiology Study - investigating lifestyle and environmental exposures and genetic variants and glioma risk in those with and without glioma.

Observational Study investigating lifestyle and environmental exposures, genetic variants and glioma risk in those with and without glioma.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12615001182583

Acronym

AGOG (Australian Genomics and Clinical Outcomes of Glioma)

Enrollment

1600

Registered

2015-11-03

Start date

2013-08-13

Completion date

2016-12-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The AGOG Epidemiology Study will study genes, lifestyle and environmental factors in people with and without brain tumours in order to identify who are at risk of developing these tumours. Who is it for? You may be eligible to join this study if you are aged 18 to 79 years and were diagnosed with glioma between January 2013 and June 2016. Study details This is an observational study, meaning that no treatment is given to participants as part of this study. Participants and up to two family members are asked to provide a blood (or saliva) sample and complete three questionnaires regarding their lifestyle and family history of glioma. Researchers will use this information, along with disease and treatment information from hospital records to identify patterns between patient lifestyles, family histories, genetics and disease treatment and outcomes. It is hoped that the findings of this study will provide a research platform for further studies into predictive factors of glioma and glioma outcomes, and for the identification of future treatment options for glioma.

Interventions

The AGOG Epidemiology Study is a hospital-based family-case-control study of glioma, collecting estimates of lifestyle, constitutional, and environmental exposures and sampling blood for genotyping and future biomarker studies. This is a retrospective observational study only - no intervention is being tested. Participants complete 3 questionnaires at one time and provide one blood sample.

Eligibility

Sex/Gender

All

Age

18 Years to 79 Years

Healthy volunteers

Yes

Inclusion criteria

Case: 1. aged 18 to 79 years 2. diagnosed with glioma (including low and high grade glioma) between January 2013 and December 2016 with histopathological confirmation. Control: 1. Aged of 18 and over the age of 79. 2. Never been diagnosed with glioma

Exclusion criteria

Case 1. Non-residents of Australia. 2. Patients who are unable to provide written informed consent, or who are deemed by their clinician to be significantly cognitively impaired, and who do not have a person responsible to provide substitute consent on their behalf. 3. Patients who are unable to complete the questionnaires themselves in English. 4. Patients under the age of 18 and over the age of 79. Control 1. Individuals who are unable to complete the questionnaires themselves in English. 2. Individuals under the age of 18 and over the age of 79. 3. Have been diagnosed with glioma

Outcome results